What is HC Wainwright's Estimate for ATOS FY2029 Earnings?

Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Stock analysts at HC Wainwright issued their FY2029 earnings per share estimates for Atossa Therapeutics in a research note issued on Thursday, January 30th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.14) for the year. HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Atossa Therapeutics' current full-year earnings is ($0.22) per share.

Several other equities research analysts have also recently weighed in on ATOS. StockNews.com cut Atossa Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, November 18th. Ascendiant Capital Markets raised their price target on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a "buy" rating in a research report on Monday, December 9th.

Atossa Therapeutics Trading Down 5.3 %

ATOS traded down $0.04 during midday trading on Monday, reaching $0.81. The company's stock had a trading volume of 754,180 shares, compared to its average volume of 789,403. The company has a fifty day simple moving average of $1.00 and a 200 day simple moving average of $1.25. The stock has a market cap of $101.27 million, a P/E ratio of -3.66 and a beta of 1.24. Atossa Therapeutics has a twelve month low of $0.72 and a twelve month high of $2.31.

Remove Ads

Institutional Trading of Atossa Therapeutics

Several institutional investors have recently modified their holdings of ATOS. Barclays PLC lifted its position in Atossa Therapeutics by 280.9% in the third quarter. Barclays PLC now owns 167,718 shares of the company's stock worth $255,000 after purchasing an additional 123,683 shares during the period. State Street Corp lifted its holdings in shares of Atossa Therapeutics by 4.2% during the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company's stock worth $2,633,000 after acquiring an additional 69,180 shares during the period. XTX Topco Ltd boosted its position in shares of Atossa Therapeutics by 101.2% during the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company's stock valued at $75,000 after acquiring an additional 24,951 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Atossa Therapeutics by 177.1% in the third quarter. JPMorgan Chase & Co. now owns 149,642 shares of the company's stock valued at $227,000 after acquiring an additional 95,643 shares during the period. Finally, Geode Capital Management LLC raised its position in Atossa Therapeutics by 1.6% in the third quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company's stock worth $4,278,000 after purchasing an additional 44,762 shares in the last quarter. Institutional investors and hedge funds own 12.74% of the company's stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.